Alkhuja Samer, Gazizov Natalya, Alexander Mary Ellen
The Commonwealth Medical College, Pocono Medical Center, 175 East Brown Street, Suite 203, East Stroudsburg, PA 18301, USA.
Case Rep Pulmonol. 2013;2013:813786. doi: 10.1155/2013/813786. Epub 2013 Sep 5.
A 16-year-old Caucasian female presented to the pulmonary clinic for a followup on her asthma. Due to the worsening of allergy-related symptoms, therapy with montelukast 10 mg daily was started and resulted in good relief of the patient's symptoms. In the nights following initiating therapy with montelukast, the patient's mother reported daily parasomnias in the form of sleeptalking and sleepwalking. Montelukast was discontinued, and that resulted in absence of the parasomnias. In a second attempt montelukast was reinstituted to control the patient's symptoms. Parasomnias were immediately reported after resuming therapy. Montelukast was then discontinued indefinitely. Our patient has never had any history of parasomnias, and since the discontinuation of montelukast, parasomnias were never reported again. Parasomnias in the form of sleeptalking or sleepwalking were not previously reported as adverse effects of montelukast. Alternative modalities to treat allergy-related symptoms in patients, who develop parasomnias while receiving montelukast, should be explored.
一名16岁的白种女性前往肺部诊所对其哮喘进行随访。由于过敏相关症状恶化，开始每日使用10毫克孟鲁司特进行治疗，患者症状得到明显缓解。在开始使用孟鲁司特治疗后的夜晚，患者母亲报告称患者每天出现说梦话和梦游形式的睡行症。停用孟鲁司特后，睡行症消失。再次尝试使用孟鲁司特以控制患者症状时，恢复治疗后立即报告出现睡行症。随后无限期停用孟鲁司特。我们的患者既往从未有过睡行症病史，自停用孟鲁司特后，再也没有报告过睡行症。说梦话或梦游形式的睡行症此前未被报告为孟鲁司特的不良反应。对于在接受孟鲁司特治疗时出现睡行症的患者，应探索治疗过敏相关症状的替代方法。
